| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22036 |
| Drug | Atezolizumab |
| Brand | Tecentriq® |
| Indication | As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC. |
| Assessment Process | |
| Rapid review commissioned | 18/05/2022 |
| Rapid review completed | 02/06/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard-of-care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/07/2022 |
| Pre-submission consultation with Applicant | 04/10/2022 |
| Full submission received from Applicant | 02/12/2022 |
| Preliminary review sent to Applicant | 05/05/2023 |
| NCPE assessment re-commenced | 02/06/2023 |
| Factual accuracy sent to Applicant | 06/07/2023 |
| NCPE assessment re-commenced | 12/07/2023 |
| NCPE assessment completed | 20/07/2023 |
| NCPE assessment outcome | The NCPE recommends that atezolizumab (Tecentriq ®) should not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
